Recursion Pharmaceuticals, Inc. RXRX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
42/100
Developing

Ranked against 712 peers in Biotechnology

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 … Full RXRX analysis →

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.74), with margins expanding over time.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.22), raising refinancing risk.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.31), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
33
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where RXRX ranks in Biotechnology

Recursion Pharmaceuticals, Inc. ranks #350 of 713 scored companies in Biotechnology by moat score — the top 49%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
346 Vera Therapeutics, Inc. VERA 42/100 Developing
347 Dyadic International, Inc. DYAI 42/100 Developing
348 MoonLake Immunotherapeutics MLTX 42/100 Developing
349 Pyxis Oncology, Inc. PYXS 42/100 Developing
350 Recursion Pharmaceuticals, Inc. RXRX 42/100 Developing
351 TScan Therapeutics, Inc. TCRX 41/100 Developing
352 Tonix Pharmaceuticals Holding C TNXP 41/100 Developing
353 CRISPR Therapeutics AG CRSP 41/100 Developing
354 PureTech Health plc PRTC 41/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How RXRX scores on the Corporate Default defenses

Pricing Power

Score 33 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 46 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 48 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 40 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 38 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 48 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RXRX's moat

What is Recursion Pharmaceuticals, Inc.'s moat score?

Recursion Pharmaceuticals, Inc. (RXRX) scores 42 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #350 of 713 scored companies in Biotechnology, the top 49%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (48/100) and its weakest is Pricing Power (33/100).

How does Recursion Pharmaceuticals, Inc. compare with other Biotechnology companies?

Recursion Pharmaceuticals, Inc. ranks #350 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Pyxis Oncology, Inc. (PYXS) at 42 just above it and TScan Therapeutics, Inc. (TCRX) at 41 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Recursion Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Recursion Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and RXRX scores: Pricing Power (33), Cost Advantage (46), Customer Stickiness (48), Capital Efficiency (40), Resilience (38), Scale & Market Position (48). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000